Techcyte’s core passion is in improving the lives of those around us. Our work to improve cytological tests don’t just benefit laboratories. Quicker, more efficient diagnoses ultimately translate to better patient outcomes.

solutions close up image of cells solutions close up image of cells
Challenge & Solution
oncology cells

Challenge & solution

As the average lifespan increases, so does the need for more laboratory tests. This increased workload requires laboratories to perform more and more tests with existing resources. At the same time, there is a worldwide shortage of qualified technicians due to retirement, competing disciplines such as molecular biology, and the fact that less and less people are entering into the field. So while the need for qualified lab personnel is increasing, the supply is decreasing. This places more load on existing personnel, and pushes laboratories to seek optimizations wherever they can. Aside from this reality, microscopy performed by humans has several disadvantages, including technician fatigue, difficult working conditions and biases.

Our patented AI-based image analysis helps lab technicians read samples more quickly and accurately than the existing systems on the market. It enables cost and time savings, which enables laboratories to produce better results in less time for less money, keeping them competitive and able to better attract and retain strong personnel.

scientists shaking hands


ARUP Laboratories 

ARUP and Techcyte are collaborating to produce the world’s first AI-augmented ova and parasite detection tool as well as an easy-to-administer SARS-CoV-2 antibody test.

Ketterthill Laboratoires d’Analyses Médicales 

The Luxembourg lab supported us in developing our bacteriology algorithm, which locates and classifies bacteriological morphotypes and is CE marked in the EU.


We partnered with ARUP Laboratories to develop Nanospot, an ultra-fast test that measures COVID-19 antibodies. NanoSpot is CE marked in the EU and is currently undergoing studies in the US. 

The test is significantly less expensive to manufacture than other SARS-CoV-2 antibody tests, performed on a spot of blood obtained through a finger prick. Our solution gives reference lab level quantified results in 30 seconds and the cost is less than the traditional lateral flow tests because the test takes place on a card made of cardstock paper.

Test results are received on mobile devices.

Learn more about Nanospot
Featured Press